|drug1200||Enoxaparin sodium Wiki||0.71|
|drug3068||Serological testing Wiki||0.71|
|D003920||Diabetes Mellitus, NIH||0.14|
|D016638||Critical Illness NIH||0.09|
There are 2 clinical trials
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to intermediate dose prophylaxis or therapeutic dose anticoagulation treatment arms.Treatment will continue for 28 days, followed by a 6 month follow-up period.
Description: Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment armMeasure: 30-day mortality Time: 30 days
Description: Comparison of length of ICU stay in days between each treatment arm.Measure: Length of Intensive Care Unit (ICU) Stay in Days Time: 6 months
Description: Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment armMeasure: Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events Time: 6 months
Description: Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria.Measure: Number of major and clinically relevant non-major bleeding events Time: 6 months
This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies. Individual studies will be conducted in multiple countries, including Australia, the UK, Argentina, Brazil and Egypt. Adult patients admitted to the hospital with confirmed SARS-CoV-2 infection, who do not require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or standard care for up to 21 days or until the patient has no respiratory symptoms. All studies will collect a minimum core dataset. The primary outcome for the meta-trial is the proportion of patients who receive invasive mechanical ventilation censored at day 28. Individual studies may have specific outcome measures in addition to the core set.
Description: Proportion of patients requiring invasive mechanical ventilationMeasure: Intubation rate Time: Day 28
Description: Number of patients showing 1 or 2 point worsening on the ordinal scaleMeasure: WHO ordinal scale COVID19 Time: Day 7
Description: Daily ratio of partial pressure of oxygen to FiO2 (PaO2/FiO2)Measure: Oxygenation Time: Day 7
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports